FDA Panel Greenlights New Injection To Prevent Respiratory Virus in Infants

An advisory committee to the FDA recommended approval of an injectable drug called nirsevimab to protect infants up to 2 years old from RSV, a leading cause of hospitalization among infants.
The injection, delivered in a single shot, was found to lower the risk of developing respiratory disease from RSV that required doctors' visits by around 70-75% for at least five months.
The company estimated that its injection could prevent up to 500,000 medical visits per year, including up to 60,000 hospital admissions
Nirsevimab is a monoclonal antibody developed by AstraZeneca and Sanofi to protect infants and young toddlers from RSV
This vote comes shortly after the FDA approved the first RSV vaccine for use among older adults